Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Reports outline breast cancer study findings from Cornell University
November 20th, 2008
According to a study from the United States, "This Practice Point commentary discusses the findings of a trial that assessed the efficacy of weekly (QW) versus once every 3 weeks (Q3W) paclitaxel or docetaxel after doxorubicin-and-cyclophosphamide-based chemotherapy in patients with node-positive or high-risk node-negative breast cancer. There were several analyses in this trial, the first comparing docetaxel with paclitaxel and the second assessing the impact of schedule of chemotherapy." "In an intention to treat analysis, there was no difference in disease-free survival between the two taxanes or between the two dosing schedules. When the four arms of the trial were...
Source: Women's Health Weekly (2008-11-20)
|
